BACKGROUND: A summary measure that reflects the global toxicity burden of a treatment is essential for comparing therapies. Current toxicity summaries are ad hoc and do not distinguish among the severities and types of toxicities. Here a clinically feasible method for estimating the toxicity burden, based on a prospective evaluation of the toxicity profile of a randomized clinical trial of 746 prostate cancer patients conducted by SWOG, is proposed. METHODS: For 308 patients who experienced severe toxicities, 2 physicians randomly selected from 14 physicians evaluated each toxicity profile and assigned a visual analogue scale score (0-10) based on their impression of the global burden of toxicities. With mixed-effects models, severity scores and a 10-point toxicity burden score (TBS) were derived from 27 predictors accounting for severe (grade 3) and life-threatening (grade 4) toxicities for each organ class of the Common Terminology Criteria for Adverse Events. RESULTS: For most organ classes, grade 3 toxicities had a TBS of 4.14 (95% confidence interval [CI], 3.65-4.63), but infections, cardiovascular events, and pulmonary events had a higher TBS with differences of 0.87 (95% CI, 0.53-1.21), 0.88 (95% CI, 0.51-1.25), and 0.73 (95% CI, 0.22-1.24), respectively. Moreover, most grade 4 events had a higher TBS than grade 3 events, except for hemorrhaging, pain, metabolic events, and musculoskeletal events. The intrarater and interrater correlations were 0.91 and 0.59, respectively. CONCLUSIONS: The burden of toxicity grades differs with toxicity types. A TBS provides a toxicity burden summary that incorporates physicians' perspectives and differentiates between severe and lifethreatening toxicities and organ classes. Cancer 2018;124:858-64.
INTRODUCTION
A comprehensive summary of all the toxicities experienced by a patient that adequately reflects the global toxicity burden is essential for the comparison of treatments. This is particularly true for cancer treatments, which are often associated with many severe adverse events. The value framework for cancer treatments from the American Society of Clinical Oncology includes 3 key elements: clinical benefit, toxicity, and the cost of drug acquisition. 1, 2 Although there is a general consensus regarding the definitions of a clinical benefit and the cost of drug acquisition, identifying a summary for toxicities resulting from cancer treatments is challenging. During the conduct of trials, toxicities are conventionally captured for a wide range of adverse events with the grading system provided by the Common Terminology Criteria for Adverse Events (CTCAE) from the National Cancer Institute (NCI). 3 The grading is specific to each adverse event, with events being defined on a scale from 1 (a mild adverse event) to 5 (death).
The convention for reporting adverse events in clinical trials is to list the most prevalent adverse events or toxicities and report the frequency of grade 3 or higher toxicities for each and across all toxicity types. To accommodate for the differences in severity between a severe toxicity (grade 3) and a life-threatening toxicity (grade 4), sometimes frequency values are provided separately. The interpretation of the overall burden of the toxicities and which treatment is in general more burdensome is left to the reader. This reporting practice is ad hoc, does not systematically differentiate between the toxicity burden of a grade 3 severe toxicity and a grade 4 life-threatening toxicity, and assumes that toxicities of a given grade are equally burdensome across organ class categories. For example, when the prevalence of grade 3 or higher toxicities is being reported, if treatment A results in a 30% frequency of grade 4 cardiac toxicities and a 10% frequency of grade 3 vomiting and treatment B results in a 5% frequency of grade 3 cardiac toxicity, a 15% frequency of grade 3 nausea, and a 20% frequency of grade 3 thrombocytopenia, the prevalence of grade 3 or higher toxicities for the 2 treatments will be identical. However, we could argue that treatment A is more toxic and burdensome. Moreover, there is no simple way to combine the effects of the various toxicities to obtain an overall burden based on a toxicity profile. This is particularly challenging when we are comparing treatments with different toxicity profiles. Thus, a more comprehensive approach for summarizing toxicity is needed to quantify the global burden of a treatment across maximal toxicity grades and types.
Several methods have been proposed for summarizing toxicity across grades and types.
1,2,4-7 All of these methods, except for the original American Society of Clinical Oncology value framework, which uses the conventional approach, summarize toxicities into an overall score with a weighted sum of individual toxicity types and grades. Most methods assume that all toxicities are equally burdensome or assign severity scores for the toxicity types on the basis of consensus with a theoretical framework. 2, [4] [5] [6] In contrast, the method proposed by Lee et al 7 estimates severity scores for individual toxicity types and grades with a regression approach in which the predictors are pre-identified treatment-related toxicities and the outcome is a burden score elicited from physicians that uses existing data based on their impression of the overall burden of all of the toxicity types and grades reported. Using a regression approach allows a reproducible and systematic way of obtaining severity scores that account for physician input on the relative burden of the toxicities. However, the major weaknesses of the study were the small sample size and the use of treatment-related toxicities as predictors. This suggests that the model would be treatment-specific and limits its applicability in a general setting because treatment-related toxicities differ by drug.
In this article, we generalize the approach proposed by Lee et al, 7 and instead of selecting the predictors to be treatment-related toxicities, we evaluate the feasibility of estimating the individual severity scores for all organ classes in the NCI CTCAE. Thus, the severity scores obtained can be applied across treatment and disease types as long as toxicity data are available for estimating them. Given the large number of covariates of interest and to ensure the relevance of the combinations of toxicities that manifest in real life trials, we used toxicity data from a large randomized trial conducted by SWOG for the elicitation process. Furthermore, to illustrate its use in practice, we applied the severity scores and the obtained model to estimate the global burden and calculate an overall toxicity burden score (TBS) for each patient in the trial based on the toxicities captured, and we compared the global toxicity burdens of the 2 arms of the trial.
MATERIALS AND METHODS

Study Design and Setting
The toxicity data were obtained from a previously reported multicenter randomized clinical trial conducted by SWOG with 746 advanced refractory prostate cancer patients. 8 The aim of the study was to compare the overall survival of patients randomized to docetaxel and estramustine and patients randomized to mitoxantrone and prednisone. Toxicity data for this trial were captured with the NCI CTCAE (version 2.0), 9 and only grade 3 or higher toxicities that were possibly, probably, or definitely related to treatment were required to be entered. Toxicity data were captured for 334 of the 746 patients. No toxicity data were captured for the remaining 412 patients. These patients could have experienced no treatmentrelated toxicities or only grade 1 or 2 treatment-related toxicities, which were not required to be captured.
The individual toxicity profiles for these 334 patients were evaluated by 14 physicians at the Columbia University Medical Center from 2014 to 2015. Nine were junior faculty members, and 5 were senior faculty members. Four were female. Three specialized in breast cancer, 4 specialized in hematology, 4 specialized in gastroenterology, and 3 specialized in other areas of oncology. Each physician was given a list of approximately 50 patients along with their corresponding toxicities and was asked to assign a score with a visual analogue scale (VAS) based on his or her impression of the combined burden of the symptoms and adverse events on the patient's overall health, quality of life, and function. A sample list and a sample VAS used for elicitation are provided in the online supporting information. The VAS was 10-cm long with anchoring for no, mild, moderate, severe, and lifethreatening events and death at 0, 2, 4, 6, 8, and 10 cm, respectively. Physicians were asked to mark their VAS score with a vertical line. The measured distance from the "no" anchor to the mark corresponded to the VAS score. The VAS was explained in detail to each physician, and a sample case was presented for illustration. Physicians were aware that the data were from a chemotherapy trial, but they were unaware of the patient characteristics and the specific treatment assigned. Moreover, physicians could look up toxicity terms in the NCI CTCAE if necessary. Each patient was rated by 2 randomly selected physicians for a total of 668 observations. Two ratings were obtained for each patient to account for the subjectivity in the Estimating Toxicity Burden With Adverse Events/Lee et al Cancer February 15, 2018 assignment of the VAS score and to allow for differences between physicians.
In addition to the 334 patients, among the patient data given to a physician, there were exact duplicates for 5 patients, which were created and included only to check for the consistency and reliability of the VAS. Thus, a total of 70 duplicate observations (14 physicians with data for 5 duplicated patients each) were used only to evaluate intrarater reliability. The study was approved by the institutional review board at Columbia University Medical Center (#AAAL7451).
Statistical Analysis
The times to complete the VAS assignments and VAS scores are summarized as means, medians, standard deviations, and ranges as appropriate. The intraclass correlations for the duplicate observations and the 2 raters are also reported. The repeated observations are visualized with scatter plots. Toxicity data from both treatment arms in the trial were pooled for the analysis. Toxicity types were grouped on the basis of the NCI CTCAE (version 2.0) system organ class because toxicity grading tends to be more standardized for related or similar toxicities. Any toxicity type within an organ class indicated the presence of a toxicity in that class. The number of toxicities by grade for each of the 19 organ systems represented was tabulated. Death was classified as a separate organ system, although it could also be captured as a grade 5 event.
For the estimation of the severity scores for the organ classes and variable selection, we excluded patients who died (n 5 15) because death was an anchor and those with only low-grade toxicities (n 5 11) because data entry for low-grade toxicities was not required. Thus, 308 of the 334 patients were used for model fitting. These 308 patients yielded 616 observations because 2 physicians provided VAS ratings for each patient. The 70 duplicate observations were not used for the estimation of the severity scores. To account for the multiple VAS scores per patient and the rating of multiple patients by the same physician, mixed-effects models with the patient and the rater as random effects were used. The covariates of interest were the presence of each grade of a given system organ class. Because deaths were excluded, a total of 18 organ system classes were evaluated with 27 covariates. For the 13 organ classes with more than 5 grade 3 or higher events, we had an indicator for grade 3 toxicity and an indicator for grade 4 toxicity; this led to 26 covariates. Finally, 1 covariate indicated the presence of a grade 3 toxicity in any of the 4 organ classes that had 1 to 5 grade 3 events (coagulation, endocrine, immunology, and skin).
For variable selection, a forward selection approach was used with an entry criterion of P < .05. Thus, we first examined the relation between VAS scores elicited from the physicians and the presence of each grade in a system organ class and selected the organ class with the smallest P value satisfying the criterion with a likelihood ratio test. Other system organ classes were included in the model by the selection of the most significant one at each step until no new organ classes satisfied the entry criterion. After all organ classes that met the entry criterion were selected, we further simplified the model by excluding covariates that did not meet the threshold. For the remaining organ system classes that included both grade 3 and grade 4 toxicity covariates, grade 3 toxicities were then compared with grade 4 toxicities to reduce the number of predictors. If they did not meet the threshold, a new variable for the presence of a grade 3 or 4 toxicity for that organ class was created and included in the final model instead. The final fitted model is displayed in the online supporting information. The models were fitted with the package lme4 in R. 10 We performed split-sample validation by randomly selecting 250 patients from the trial as a training data set to construct the model, and we made sure that all physicians were represented and that both ratings for the same patient were included. The remaining 58 patients were reserved for validation purposes. Split-sample validation was conducted 5 times, and the results were compared. The TBS obtained on the basis of the model was plotted against the elicited VAS scores from the physicians. Mean square errors and mean absolute errors were used to evaluate the performance of the model in the validation set.
Furthermore, to illustrate the value of the severity scores and the model in an application setting, we compared the TBS in the docetaxel and estramustine arm (n 5 374) with the TBS in the mitoxantrone and prednisone arm (n 5 371). With the TBS as the outcome, Fisher's exact test was used to compare the proportions of patients suffering a moderate to disabling burden or death (TBS > 4) and patients suffering a severe to disabling burden or death (TBS > 6) by treatment.
RESULTS
The median time for completing the VAS assignments was 11 minutes (range, 7-18 minutes). There were no significant differences in completion time by rank or sex. A total of 109 toxicity types were present among 19 system organ classes in the 334 patients used to elicit the VAS. The distribution of toxicity grades across the system organ classes is displayed in the online supporting information.
Original Article
When the VAS scores from the 2 raters were averaged, 28% had an average score between 0 and 4, 44% had an average score between 4 and 6, 20% had an average score between 6 and 8, 3% had an average score between 8 and 10, and 4% died during treatment. The mean average VAS score was 5.14 with a standard deviation of 1.92. The intrarater correlation for the 5 duplicated VAS burden scores across the 14 physicians was 0.91. Figure 1A displays a scatter plot of the 70 duplicate measures across the 14 physicians. The interrater correlation for any 2 pairs of raters was 0.59. Figure 1B displays a scatter plot of the VAS scores for the 250 patients selected for the training data set for the 2 randomly selected physicians.
The estimated severity scores for the presence of a single grade 3 or 4 toxicity based on our final model are displayed in Table 1 by system organ class. For most organ classes, grade 3 toxicities had a TBS of 4.14 (95% confidence interval [CI], 3.65-4.63). Grade 3 cardiovascular events, infections, and pulmonary events had significantly higher scores than grade 3 events in other system organ Moreover, grade 4 cardiovascular, hematologic, gastrointestinal, genitourinary, and neurological events and constitutional symptoms had significantly higher scores than grade 3 events of the same organ classes with differences of 1.88 (95% CI, 1.22-2.54), 1.56 (95% CI, 1.24-1.87), 1.80 (95% CI, 0.84-2.76), 3.24 (95% CI, 1.11-5.37), 2.62 (95% CI, 1.41-3.86), and 1.02 (95% CI, 0.07-1.97), respectively. However, grade 4 infections and pulmonary events did not differ significantly from grade 3 infections and pulmonary events because their respective grade 3 events were increasingly burdensome. Grade 4 hepatic events had a severity score similar to the score for grade 3 adverse events for other system organ classes. Moreover, the severity scores for grade 4 hemorrhage, metabolic, and musculoskeletal events and pain were similar to those for grade 3 events of the same organ class. To calculate the TBS for a patient with multiple grade 3 or higher toxicities, the equation in Table 2 can be used. The coefficients for the individual grades and organ classes can be interpreted as the additional severity due to toxicity for that particular grade and organ class. Table 2 also displays several examples of TBS calculations with the CTCAE. Figure 1C ,D displays the TBS versus the mean VAS score assigned by the 2 raters in the training and validation data set. The mean square error and the absolute error for the training data set were 1.36 and 0.90, respectively. For the validation data set, they were 1.02 and 0.81, respectively. Thus, on average, the TBS differed by 1 unit from the average assigned VAS score from the 2 raters. Moreover, the 5 repeated split-sample validations yielded very similar results.
To illustrate the use of a TBS as a global summary of toxicity, for patients with at least 1 grade 3 or higher toxicity, a TBS was obtained with the severity scores and the model. Patients who were excluded from the model were assigned a TBS as follows: patients without toxicities or with only low grade toxicities were assigned a TBS of 0, and patients who died during treatment were assigned a TBS of 10. One of the 746 patients was missing treatment information. Furthermore, 51% (190 of 374) in the docetaxel and estramustine arm and 32% (118 of 371; P < .001) in the mitoxantrone and prednisone arm, respectively, suffered a moderate to disabling burden or death (TBS > 4). However, 11% and 7% (P 5 .09) suffered a severe to disabling burden or death (TBS > 6). This suggests that although similar proportions of patients had severe to disabling toxicities with docetaxel and estramustine and with mitoxantrone and prednisone, a significantly higher proportion of patients experienced a moderate to severe toxicity burden in the docetaxel and estramustine arm.
DISCUSSION
We have presented a new approach for estimating the global toxicity burden with toxicities captured in standard clinical trial practice via the NCI CTCAE. The approach differentiates between grade 3 and 4 toxicities and distinguishes between toxicity types. Our results suggest that a distinction should be made between severity grades of the various types of toxicities. For most organ classes, grade 4 toxicities are considered significantly more burdensome than grade 3 events of the same class. However, for metabolic and musculoskeletal events and pain, grade 4 events are considered as equally burdensome as grade 3 events, and grade 3 infections and cardiovascular and pulmonary events are considered more burdensome than grade 3 events of other organ classes. Moreover, according to the physicians' ratings, many grade 3 and even grade 4 events are associated with a moderate burden and are not considered severely burdensome or dose-limiting. This may suggest that the current definition of dose-limiting toxicity used in dose-finding clinical trials should be revised and include not all grade 3 or higher nonhematologic toxicities and grade 4 or higher hematologic toxicities but only those considered severely burdensome. These estimates for the severity scores and the equation for calculating the TBS can be used across treatment and disease types because the model is dependent on them only insofar as toxicity data are available for estimating the severity scores. If data are available, the assignment of the VAS score is independent of the treatment or disease type. Moreover, physicians were unaware of patient information when they were assigning VAS scores. Although one option was to use simulated toxicity data for the elicitation of the VAS, we chose to use existing trial data to ensure that the combinations of toxicities used for elicitation were clinically relevant.
This article has several limitations that can be improved in future research. Further research to fine-tune the severity scores with physicians from several clinical centers in a prospective setting with a wider range of toxicity types and grades would be beneficial for generalizing the results. The estimated effects for some toxicity types are based on sparse data, and in some cases, the lack of significance may be due to a lack of power. For example, using a threshold of P < .10 for model selection instead added the presence of grade 4 pain to the final model. Moreover, we collapsed the toxicity types with fewer than 5 events for statistical convenience, and ideally we would want to estimate them separately. Implementing the collection of the VAS in several multicenter trials across a wide range of treatments and primary disease sites would help to validate the approach because we would be able to evaluate the heterogeneity of clinical sites and would have larger sample sizes for the various toxicity types. This should be done before the method is more widely applied in practice. Moreover, in this study, the data were limited for several grade 4 events, and we evaluated only the burden of grade 3 or higher toxicities. Thus, the current study does not allow us to evaluate the burden of low-grade toxicities (grade 1 and 2) in comparison with severe adverse events or to learn about the aggregate effects of low-grade toxicities. Because our previous work suggests that the aggregate effect of low-grade toxicities can be as taxing as a severe toxicity, 7 future prospective studies are needed to standardize the collection of low-grade treatment-related toxicities and assess the burden of these events to enhance the model before it is applied more widely. This is particularly important in the context of new anticancer treatments. 11, 12 The current study is limited to the summary of the toxicity burden with only the maximum toxicity grade for the toxicity types based on the current standard reporting of toxicities for clinical trials and the value framework. Ideally, the duration and chronicity of these toxicities should also be taken into account when the burden of toxicities is being summarized. Thus, further research is also needed to evaluate the impact of the toxicity duration and sequelae due to the toxicity on the overall toxicity burden. 4, 11, 12 Undoubtedly, grade 3 nausea that lasts for 1 day is not as burdensome as nausea that lasts for a month. Although approaches to reporting and depicting the duration of individual adverse events 13 and methods for analyzing quality-adjusted survival without symptoms have been proposed, 14 methods for estimating the toxicity burden that account for duration are unavailable. We and others have shown the importance of duration and chronicity in the context of new anticancer treatments and the need for using methods that account for these for identifying a more tolerable dose of treatment. 11, 12, [15] [16] [17] More research also is needed to evaluate the burden of sequelae resulting from the toxicities. Another limitation is that the toxicity data were captured with the NCI CTCAE (version 2.0), which has fewer system organ classes. Versions 3.0 and 4.0 have reclassified some of the adverse event types, and thus, it would be interesting to study the impact of these categorizations on the severity scores. Moreover, we present only the physician perspective of burden. Research has shown that physicians' perspectives may differ from those of nurses and patients. Moreover, the patient voice is critical when one is evaluating the burden of toxicities. Comparing the VAS scores among them and their respective toxicity severity scores may help us to understand the underlying reasons for these differences. In the future, by implementing a prospective collection of more detailed information on toxicity with the current version of the NCI CTCAE, the patient-reported version of the CTCAE, 18 and the VAS from patients, nurses, and physicians, we can further improve the summary methods proposed and obtain a summary method that can be more widely used in practice.
In summary, research in understanding the burden of treatment toxicities is challenging and much needed. In this article, we take a step by defining a novel summary of the global toxicity burden that is particularly useful when we are comparing treatments associated with different toxicities, and it can be easily included in standard adverse event reporting.
FUNDING SUPPORT
This work was supported by the American Cancer Society (grant MRSG-13-146-01-CPHPS) and the National Cancer Institute (grant 1UG1CA189974-01 to SWOG).
